Head-to-head evidence
Olanzapine (TV-44749) vs Olanzapine (Zyprexa)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (TV-44749)
Developed by Teva Pharmaceutical Industries
NCT05693935 · Phase 3 · completed
The 675-participant study was randomized, quadruple-blind, and placebo-controlled, with approximately 165 to 169 participants per blinded treatment group. Its primary clinical endpoint, change in PANSS total score at week 8, was significantly better with each TV-44749 dose than with placebo (all adjusted p<0.0001), supporting a strong evidence rating for the blinded efficacy comparison.
Olanzapine (Zyprexa)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00712686 · Phase 3 · completed
The study was a large randomized, double-blind, active-controlled comparison of aripiprazole and olanzapine, with clinical outcomes including PANSS symptom scores. Because the registry does not report whether either primary endpoint was met, the treatment comparison cannot be judged as positive, negative, or mixed.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (TV-44749)'s landscape · Olanzapine (Zyprexa)'s landscape